iStock-1168200027.jpg

MHA112

Antibody Drug Conjugate

MHA112 is an antibody that has the ability to target primary solid tumors while simultaneously targeting any metastases in the draining lymph node and secondary tumors.

 

MHA112

Antibody Drug Conjugate

MHA112 targets a specific protein only expressed in specialized venules contained in the lymphatic system.  These specialized venules have been shown to proliferate in and around solid tumors, expressing the same protein targeted by MHA112.

iStock-1266882540.jpg
 
iStock-1168199872.jpg

MHA112

Antibody Drug Conjugate

By conjugating MHA112 to powerful active pharmaceuticals, we can create a highly effective treatment for primary cancer tumors as well as their metastases

 

MHA112

Antibody Drug Conjugate

The company and its research partners have developed a significant amount of compelling pre-clinical data in multiple solid cancer models in preparation for an IND filing with the FDA.



iStock-1136507405_edited_edited.jpg
 

857 529 6265

200 Clarendon Street, Fl 17,
Boston MA 02116

  • Facebook
  • Twitter
  • LinkedIn

©2020 by NanoTomer, Inc.. Proudly created with Wix.com